Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.31 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17240262 | 0.98 | CYP19A1 (0.32) | CYP19A1 | |
| SCHEMBL15797626 | 0.76 | LOX (0.33) | CYP19A1KDM4E | |
| SCHEMBL15797553 | 0.74 | LOX (0.31) | CYP19A1 | |
| SCHEMBL15797625 | 0.74 | CYP19A1 (0.39) | CYP19A1MEN1KMT2A | |
| SCHEMBL15797551 | 0.72 | CYP19A1 (0.37) | CYP19A1MEN1KMT2A | |
| SCHEMBL15797309 | 0.71 | CNR1 (0.35) | CYP19A1MEN1KMT2A | |
| SCHEMBL15797410 | 0.69 | CNR1 (0.33) | MEN1KMT2A | |
| SCHEMBL14970048 | 0.67 | PDGFRB (0.47) | PDGFRBPDGFRA | |
| SCHEMBL17240229 | 0.66 | APLNR (0.32) | — | |
| SCHEMBL24967981 | 0.64 | L3MBTL1 (0.47) | KMT2AKDM4EPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9718774-B2 | Indole carboxamide derivatives as P2X7 receptor antagonist | IDORSIA PHARMACEUTICALS LTD (CH) | 2017-08-01 | — | — | US | disclosed |
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | ACTELION PHARMACEUTICALS LTD (CH) | 2015-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322008-A1 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONIST | P2RX3, P2RX7, P2RX1 | CYP19A1 2212/4885MEN1 3139/4885KMT2A 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.